|
|
|
|
|
|
|
|
|||
|
|
|
|
|||||||
|
|
|
||||||||
|
|
|
||||||||
|
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
|
Join
the Cherab
Foundation's
free email support discussion list: For
information about communication impairments, see Cherab's
partner informational site, Speechville
Express Read more about The Late Talker, a new book for families of children who are late to talk. |
November
5, 2001
To cover the travel expenditures of the doctors attending this meeting, we are asking for a suggested five dollar per person donation at the door. Please RSVP to Melanie DePoortere at md070264@aol.com or Suzanne Smolyar at suzanne@tauto.com or suzannes@VINTRANET.com or call Suzanne at 212-659-0506 Presenters:
Cherab
Foundation
Scientific Staff
Robert Katz, PhD, President, Omega-3 Research Institute,
Inc.,
Bethesda, MD Marilyn Agin, MD, Medical Director, Early Intervention, New York City, NY Lori Roth, MA, CCC-SLP, Speech Pathologist, Cherab Foundation, NJ Topic: "Lisa
Geng, President, Cherab
Foundation
had strong faith in what she called "healing power of essential fatty
acids (EFAs) in verbal apraxia". She used the internet effectively to
share her belief with other parents with apraxic children. By early
this summer it was clear that the anecdotal stories should be urgently
placed on a scientific basis. She asked Dr. Marilyn Agin and me to suggest
scientific approaches to the entire issue of EFA supplementation in
verbal apraxia. We set out, through Cherab,
to organize the First Conference for Therapy of Verbal Apraxia/Dyspraxia,
July 23-24, Headquarters Plaza Hotel, Morristown, New Jersey, documented
the outcomes of EFA supplementation through reports by speech pathologists,
analyzed the reports, assembled a venerable group of experts and, following
their recommendations, undertook the preparations for a randomized,
placebo-controlled double blind clinical trial. This trial is absolutely
essential to allow broad professional scrutiny of this potential new
therapeutic modality. After
presenting our findings at the "Fatty Acids in
Neurodevelopmental Disorders-2001," September 20-21, St. Anne's, College, Oxford University, Oxford, U.K., followed by extensive discussions and planning, we assembled the clinical trial group and designed the clinical protocol. The presentation will lead the audience through the above process and will solicit reactions to the proposed protocol." Speaker Biographies: Marilyn C. Agin, MD, Medical Director, Cherab Foundation, graduated from New Jersey Medical School in 1986, followed by a combined residency in Pediatrics and Physical Medicine and Rehabilitation at New York University Medical Center. She is board certified in both fields. Prior to medical school, Dr. Agin received her master's degree in Communication Disorders and was a practicing speech pathologist. Currently, Dr. Agin is the Medical Director of the New York City Early Intervention Program and does private neurodevelopmental evaluations primarily for children with communication disorders, learning disabilities, and autism. She is a member of the New York City chapter of the Committee on Children with Disabilities of the American Academy of Pediatrics (AAP), and has been appointed to the Executive Council of the New York City chapter of the AAP. Robert
Katz, PhD, Director for EFA Research, Cherab
Foundation,
received his degree in Organic/Medicinal Chemistry from the Hebrew
University, Jerusalem in 1972. During his postdoctoral fellowship
(1972-1973) at the National Institutes of Health (NIH), Bethesda,
Maryland, he worked in computer-assisted drug design of analgesics
and molecular pharmacology of neurotransmitters. From 1978 to 1993,
Dr. Katz was Director of Metabolic Diseases Research Program, National
Institute of Diabetes, and Digestive and Kidney Diseases, NIH, where
he administered and managed nation-wide research programs in membrane
structure and function, membrane protein crystallization, structural
biology (proteomics), enzyme replacement and gene therapy, etc. He
organized workshops and conferences in these areas and identified
research directions in need of development. Since leaving the NIH
full time position (1993), Dr. Katz has developed DHA- and EPA- derivatized
polycationic-lipophilic drug carriers to the CNS. In 1998 he founded
the Omega-3 Research Institute, Inc. (O3RI), where he co-organized
international workshops on omega-3 fatty acids in brain function,
in diabetes and its cardiovascular complications, in molecular and
cellular aspects of cancer and recently in verbal apraxia/dyspraxia.
During the last year Dr. Katz founded the Consortium for Brain Fatty
Acids, O3RI, a "center without walls" that is providing a broad range
of expert research support to parties that require such. Dr. Katz
is currently a consultant to the National Institutes of Health. In
addition, Dr. Katz is co-developing the Cherab
Foundation's
EFA-based programs.
Lori
L. Roth, MA, CCC-SLP, is a Cherab
Foundation
Speech-Language
Pathologist and Oral Motor Specialist with over 25 years of experience. She received her BA degree in Psychology from G. Washington University in Washington, D.C. in 1972. In 1974 she was awarded her Masters of Speech and Audiology from the Catholic University of America in Washington, DC. Ms. Roth's experience includes home- and hospital-based rehabilitation, private and public school intervention and private practice. Lori Roth was instrumental in establishing an Infant Stimulation Program (called Early Intervention) in Annapolis, Maryland. She has mentored and trained graduate students in Speech and Language Pathology from New York University, Columbia University, Montclair State University and The College of New Jersey as well as practicing therapists in the State of New Jersey. Ms. Roth has presented professional workshops for colleagues and regularly acts as a consultant for private and public schools.
|
|
||
|
|
Cherab
Foundation
|
|
|
|
|
|
